

REC REF	IRAS NO	Full TITLE	Minimum No of Recruits Agreed	Maximum No. of Recruits Agreed	Date Agreed to Reach Target	Reason for Closure	Total No. Recruited at Target Date	Date Trial Closed to Recruitment	Total Recruitment to Trial
13/LO/1252	135692	The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum	3	3	01/02/2016	Recruitment completed	3	01/07/2016	3
16/NW/0147	198056	Odyssey DM- A Randomised, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidaemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy	4	4	01/10/2016	Recruitment completed	0	01/10/2016	0
13/NE/0269	134646	TESARO: A Phase 3 Randomised Double blind Trial of Maintenance with Niraparib versus Placebo in Patients with Platinum Sensitive Ovarian Cancer	2	2	31/12/2015	Recruitment completed	2	30/09/2016	2
15/LO/1829	187483	ROSACEA: Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety & Efficacy of Once-Daily CLS001 Topical Gel vs Vehicle Administered for 12 Weeks to Subjects with Papulopustular Rosacea with a 4 Week FU Period	2	5	05/04/2016	Recruitment completed	3	26/10/2016	3
14/SC/0032	142458	SPIRE 1 : B1481022 Phase 3 multi-center, double-blind, randomized, Placebo-controlled, parallel group evaluation of the Efficacy, safety, and tolerability of pf-04950615, in reducing the Occurrence of major cardiovascular events in high risk Subjects	5	15	20/12/2015	Recruitment completed	15	22/07/2016	15
14/LO/2011	159926	A prospective Randomised, open label, blinded endpoint (PROBE)study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg b.i.d.) plus clopidogrel or ticagrelor vs triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAf) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI)	2	3	31/08/2016	Recruitment completed	4	31/10/2016	4